

Steroid and xenobiotic receptor (SXR), cytochrome P450 3A4 and multidrug resistance gene 1 in human adult and fetal tissues

Yasuhiro Miki^{a,*}, Takashi Suzuki^a, Chika Tazawa^a, Bruce Blumberg^b, Hironobu Sasano^a

^a Department of Pathology, Tohoku University Graduate School of Medicine, 2-1 Seiryomachi, Aoba-ku, Sendai, Miyagi-ken 980-8575, Japan

^b Department of Developmental and Cell Biology, University of California, Irvine, CA 92697-2300, USA

Received 22 January 2004; accepted 3 December 2004

Abstract

The steroid and xenobiotic receptor (SXR) has been demonstrated to play an important role in the regulation of the cytochrome P450 3A4 gene (CYP3A4) and multidrug resistance gene 1 (MDR1) by both endogenous and xenobiotic substrates. SXR and its rodent ortholog PXR exhibit marked differences in their ability to be activated by xenobiotic inducers. This suggests that results obtained by rodent models may not always accurately predict responses to the same compounds in humans. SXR expression was demonstrated in the human liver and intestine, but its systemic distribution remains unknown. Therefore in this study, we first characterized the expression of SXR and its target genes CYP3A4, and MDR1 in human adult and fetal tissues using quantitative RT-PCR, immunoblotting, and combined laser capture microscopy and RT-PCR analysis. SXR mRNA and protein are expressed in adult and fetal liver, lung, kidney, and intestine. There is a close association between the expression of SXR and its target genes in all of the tissues examined. The amounts of SXR mRNA in the liver and intestine reached maximal levels in young adults (15–38 years old) and then subsequently decreased to less than half of the maximal levels with aging. These findings demonstrated age-related differences in the body's capacity to metabolize steroids and xenobiotic compounds and suggest an important role for SXR and its target genes, CYP3A4 and MDR1 in this process.

© 2004 Elsevier Ireland Ltd. All rights reserved.

Keywords: Steroid and xenobiotic receptor; CYP3A4; MDR1

1. Introduction

The steroid and xenobiotic receptor, SXR (Blumberg et al., 1998a) was originally isolated as a potential homolog of the *Xenopus laevis* benzoate X receptor (Blumberg et al., 1998b). This receptor is also referred to as human pregnane X receptor (hPXR; Lehmann et al., 1998) or human pregnane activated receptor (hPAR; Bertilsson et al., 1998). SXR positively regulated transcription of cytochrome P450 3A4 (CYP3A4; Bertilsson et al., 1998; Blumberg et al., 1998a; Lehmann et al., 1998) and multidrug resistance gene (MDR1; Geick et al., 2001; Willson and Kliewer, 2002), also known as ABCB1 (ATP-binding cassette B1) and has been demonstrated to be a master or dominant regulator of xenobiotic metabolism (Synold et al., 2001; Xie and Evans,

2001; Dussault and Forman, 2002; Kliewer et al., 2002). Metabolism of drugs, xenobiotic compounds, and other endogenous/exogenous substrates such as steroids generally begins with oxidation by cytochrome P450 (CYP) phase I enzymes followed by phase II reactions in which the hydroxylated metabolite is conjugated to a polar ligand. The drug efflux pump P-glycoprotein (P-gp), encoded by MDR1 and located on the cellular plasma membrane, is the final component in these xenobiotic detoxification cascades (Michalets, 1998). The most significant cytochrome P450 for drug and xenobiotic metabolism is CYP3A, which constitutes 30 and 70% of the whole CYPs in human livers and intestines, respectively (de Wildt et al., 1999). The CYP3A subfamily consists of at least three isoforms, CYP3A4, CYP3A5 and CYP3A7 (Nelson et al., 1996). Recently, a novel isoform, CYP3A43 has been characterized (Domanski et al., 2001; Gellner et al., 2001; Westlind et al., 2001), but its functions including regulation by SXR still remains largely unknown.

* Corresponding author. Tel.: +81 22 717 8050; fax: +81 22 717 8051.
E-mail address: miki@patholo2.med.tohoku.ac.jp (Y. Miki).

Expression of CYP3A4 and CYP3A7 is induced by substrates for these enzymes largely via activation of SXR.

SXR has been demonstrated to be closely associated with the expression of CYP3A4 and MDR1 in human tissues (Bertilsson et al., 1998; Blumberg et al., 1998a; Lehmann et al., 1998; Geick et al., 2001). In addition, it is well known that the capacity for metabolism and excretion of drugs decreases with advancing age and the expression of CYP3A in human liver has been shown to vary with development (Greenblatt et al., 1982; Osterheld, 1998) but its details still remain unknown. Therefore, we hypothesized that the decreased capacity for drug and xenobiotic metabolism was related to changes in SXR expression of human tissues.

SXR was reported to be present in adult human liver, small intestine, and large intestine (Bertilsson et al., 1998; Blumberg et al., 1998a; Lehmann et al., 1998), but its cellular localization and expression in other tissues has also remained largely unknown. CYP3A and MDR1 expression has been detected in adult and fetal lung, kidney, and other human tissues (Thiebaut et al., 1987; Cordon-Cardo et al., 1990; van Kalken et al., 1992; Anttila et al., 1997; de Wildt et al., 1999) but correlation between the expressions of SXR and CYP3A or SXR and MDR1 mRNAs remain unknown. Metabolism and elimination of endogenous and exogenous substrates is very important in the fetus as well as in adults, but SXR mRNA expression in human fetal tissues is unknown. Therefore, in this study, we characterized the expression of SXR and its target genes CYP3A4, and MDR1 in human adult and fetal tissues obtained from autopsy or elective termination using quantitative RT-PCR, immunoblotting, and combined laser capture microscopy and RT-PCR analysis in order to further study the possible roles of SXR in human xenobiotic metabolisms.

2. Materials and methods

2.1. Tissue preparation

The age and gender of the subjects examined are summarized in Table 1a. The number of subjects examined in each experiment was summarized in Table 1b. The subjects have been divided into four age groups as follows: neonatal, 0 years old; young, 15–38 years old; middle aged, 45–65 years old; elderly, 67–85 years old. Human neonatal and adult livers, kidney, lung, small/large intestine, and other tissues (subjects No. 13, 15, 19, and 23) were obtained from autopsy at the Department of Pathology, Tohoku University Hospital within 2 h postmortem. Human fetal tissues (gestation ages, 14–21 weeks) were obtained after elective termination in normal pregnant woman at Nagaike Maternal Clinic (Sendai, Japan). None of the patients received corticosteroids prior to autopsy. The committee on the ethics of Tohoku University School of Medicine approved this research protocol, and informed consent for this study was obtained from pregnant women before elective termination.

2.2. Polymerase chain reaction (PCR)

2.2.1. Reverse transcription (RT)

Total RNA was extracted by homogenizing frozen tissue samples in TRIzol reagent (Invitrogen Life Technologies, Inc., Gaithersburg, ND). In order to rule out possible genomic DNA contamination, the RT step was performed in the absence of SUPERScript™ II Reverse Transcriptase (Invitrogen Life Technologies, Inc.) followed by PCR. The RT-PCR products were electrophoresed and no bands were detected in these control samples (data not shown). The re-

Table 1a
Summary of the subjects examined

No.	Age ^a	Sex	Mean ^a age	Group	No.	Age ^a	Sex	Mean ^a age	Group
1	14	M	18.1	Fetus (n = 8)	21	44	F	57.0	Middle (n = 8)
2	15	M			22	49	M		
3	18	M			23	51	M		
4	18	M			24	59	M		
5	19	M			25	60	M		
6	20	M			26	63	F		
7	20	F			27	65	M		
8	20	F			28	65	F		
9	0	M	0	Neonatal ^b (n = 4)	29	67	F	75.9	Elderly (n = 8)
10	0	M			30	69	F		
11	0	F			31	72	F		
12	0	M			32	74	M		
13	15	F	28.9	Young (n = 8)	33	75	M	75.9	Elderly (n = 8)
14	17	M			34	81	F		
15	24	M			35	83	M		
16	28	M			36	86	F		
17	34	F							
18	37	M							
19	38	F							
20	38	F							

^a Fetus, weeks; neonatal-elderly, years. M, male; F, female.

^b No. 9, 1 day after birth; No. 10, 8 days after birth; No. 11, 14 days after birth; No. 12, 24 days after birth.

Table 1b
Summary of the subjects examined—the specimens number used in each experiments

Group	PCR		Immunoblotting						LCM ^a				
	Liver, kidney, lung		Intestine (small and large)		Liver	Kidney	Lung	Intestine		Kidney	Small intestine		
	Nos. 1–8 (n=8)	Nos. 9–12 (n=4)	Nos. 13–20 (n=8)	Nos. 21–28 (n=8)	Nos. 1, Nos. 5–8 (n=5)	Nos. 9–12 (n=4)	Nos. 13, 19 (n=2)	No. 19 (n=1)	No. 19 (n=1)	No. 19 (n=1)	No. 19 (n=1)	21 weeks M, F (n=2)	21 weeks M, F (n=2)
Fetus	Nos. 1–8 (n=8)	Nos. 9–12 (n=4)	Nos. 13–20 (n=8)	Nos. 21–28 (n=8)	Nos. 1, Nos. 5–8 (n=5)	Nos. 9–12 (n=4)	Nos. 13, 19 (n=2)	No. 19 (n=1)	No. 19 (n=1)	No. 19 (n=1)	No. 19 (n=1)	21 weeks M, F (n=2)	21 weeks M, F (n=2)
Neonatal	Nos. 1–8 (n=8)	Nos. 9–12 (n=4)	Nos. 13–20 (n=8)	Nos. 21–28 (n=8)	Nos. 1, Nos. 5–8 (n=5)	Nos. 9–12 (n=4)	Nos. 13, 19 (n=2)	No. 19 (n=1)	No. 19 (n=1)	No. 19 (n=1)	No. 19 (n=1)	17 years M; No. 19 (n=2)	17 years M; No. 19 (n=2)
Young	Nos. 1–8 (n=8)	Nos. 9–12 (n=4)	Nos. 13–20 (n=8)	Nos. 21–28 (n=8)	Nos. 1, Nos. 5–8 (n=5)	Nos. 9–12 (n=4)	Nos. 13, 19 (n=2)	No. 19 (n=1)	No. 19 (n=1)	No. 19 (n=1)	No. 19 (n=1)	55 years M (n=1)	55 years M (n=1)
Middle	Nos. 1–8 (n=8)	Nos. 9–12 (n=4)	Nos. 13–20 (n=8)	Nos. 21–28 (n=8)	Nos. 1, Nos. 5–8 (n=5)	Nos. 9–12 (n=4)	Nos. 13, 19 (n=2)	No. 19 (n=1)	No. 19 (n=1)	No. 19 (n=1)	No. 19 (n=1)	57 years M (n=1)	57 years M (n=1)
Elderly	Nos. 1–8 (n=8)	Nos. 9–12 (n=4)	Nos. 13–20 (n=8)	Nos. 21–28 (n=8)	Nos. 1, Nos. 5–8 (n=5)	Nos. 9–12 (n=4)	Nos. 13, 19 (n=2)	No. 19 (n=1)	No. 19 (n=1)	No. 19 (n=1)	No. 19 (n=1)	76 years M (n=1)	76 years M (n=1)

^a The cases used LCM analysis different from the cases demonstrated Table 1 (except for No. 19) were used. No., demonstrated in Table 1a; LCM, laser capture microdissection; M, male; F, female; –, no specimens were available for study.

sulting cDNA was used as a template for polymerase chain reaction (PCR).

2.2.2. Semi-quantitative real-time RT-PCR

Real-time PCR was carried out using the LightCycler System (software version 3.5.3) with SYBR Green (LightCycler FastStart DNA Master SYBR Green I, Roche Diagnostics GmbH, Mannheim, Germany). PCR was set up at 4 mM MgCl₂, 10 pmol/l of each primer (Table 2; Blumberg et al., 1998a; Faneyte et al., 2001; Miki et al., 2002; Miyoshi et al., 2002) and 2.5 U *Taq* DNA polymerase (Invitrogen Life Technologies, Inc.). An initial denaturing step of 95 °C for 1 min was followed by 40 cycles, respectively, of 95 °C for 0 s; 15 s annealing at 68 °C (SXR), 62 °C (CYP3A4, and MDR1) or 60 °C (GAPDH); and extension for 15 s at 72 °C. In initial experiments, PCR products were purified and subjected to direct sequencing (ABI PRISM BigDye Terminator v3.0 Cycle sequencing Kit and ABI PRISM 310 Genetic Analyzer, Applied Biosystems, CA, USA) to verify amplification of the correct sequences. RNA from cultured human liver cells [HuH7, human hepatocellular carcinoma obtained from Cell Resource Center for Biomedical Research, Institute of Development, Aging and Cancer, Tohoku University (Sendai, Japan)] were used for SXR, CYP3A4, and MDR1 as a positive control. Negative control experiments included those lacking cDNA substrates to check for the presence of exogenous contaminant DNA. No amplified products were detected under these conditions. To determine the quantity of target cDNA transcripts, cDNAs of known concentration for SXR, CYP3A4, MDR1, and the house-keeping gene, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were used to generate standard curves for real-time qPCR. The mRNA level in each case was represented as a ratio of GAPDH, and was evaluated as a ratio (%) compared with that of each positive control. Conventional quantitative PCR requires the utilization of a defined cDNA in the construction of a standard curve, but employment of the LightCycler utilizing a purified PCR product cDNA of known concentration can semi-quantify PCR products (Miki et al., 2002).

2.2.3. Microdissection/RT-PCR

The specimens used microdissection/RT-PCR are summarized in Table 1b. Normal adult kidney tissues were obtained from two male patients who underwent surgical treatment for renal atrophy (17 years old) and renal cell carcinoma (55 years old), respectively. Normal adult small intestinal tissues were obtained from two male patients who underwent surgical treatment (57 and 76 years old). Fetal kidney and small intestine were obtained from the same two fetuses (18 weeks, male and female) after elective termination. Laser Capture Microdissection LCM was performed using a CRI-337 (Cell Robotics, Inc., Albuquerque, NM). Approximately 100 cells were laser-transferred from the glomerulus, urinary tubules, and the interstitium of adult and fetal kidney. Epithelium, tela submucosa and tunica muscularis of adult and fetal small intestine were also transferred. Total RNA was extracted from

Table 2
Primer sequences used in RT-PCR analysis

Cdna	GeneBank accession No.		Sequence	Size (bp)	Ref.
SXR ^a	NM022002	Forward	5'-TCC TAC ATT GAA TGC AAT CGG-3'	218	Blumberg et al. (1998a)
		Reverse	5'-CAT CAA TGC TCA GCA CAC CC-3'		
CYP3A4	NM017460	Forward	5'-CAG GAG GAA ATT GAT GCA GTT TT-3'	80	Miyoshi et al. (2002)
		Reverse	5'-GTC AAG ATA CTC CAT CTG TAG CAC AGT-3'		
MDR1	AF616535	Forward	5'-AAG CCA CGT CAG CTC TGG ATA-3'	73	Faneyte et al. (2001)
		Reverse	5'-CGG CCT TCT CTG GCT TTG T-3'		
GAPDH	M33197	Forward	5'-TGA ACG GGA GCT CAC TGG-3'	307	Miki et al. (2002)
		Reverse	5'-TCC ACC ACC CTG TTG CTG TA-3'		

^a Oligonucleotide primers for SXR were designed using the previously published cDNA sequence.

laser-transferred cells according to a RNA microisolation protocol (Emmert-Buck et al., 1996; Niino et al., 2001). Total RNA from the microdissected kidney and intestine tissue was reverse transcribed and cDNA was amplified in 25 µl of a PCR mix consisting of GeneAmp, 1× PCR Gold Buffer (PerkinElmer Life Sciences, Inc.), 1.5 mM MgCl₂, 200 µM dNTP, and 0.125 unit of AmpliTaq Gold (PerkinElmer Life Sciences, Inc.) under the following conditions: initial denaturing at 95 °C for 10 min followed by 40 cycles of 1 min at 94 °C, 1 min at 55 °C, and 1 min at 72 °C, after which PCR products were subjected to a final extension step for 7 min at 72 °C. Primers used for PCR amplification were described above.

2.3. Immunoblotting

The specimens used immunoblotting are summarized in Table 1b. Approximately 100 mg of human tissues [liver, kidney, lung, spleen, stomach, small intestine, large intestine] obtained from a 38-year-old woman (No. 19 in Table 1) and livers [0,15, 24, 44, 63, and 86 years old (No. 9, 13, 21, 26, and 36 in Table 1). fetus; 18 wk (No. 4 in Table 1)] were homogenized in 500 µl of triple detergent buffer.

Immunoblotting was performed using 20 µg of protein. Following electrophoresis, protein was transferred on to Hybond P polyvinylidene difluoride membrane (Amersham Bio-

Table 3
Summary of semi-quantitative PCR for SXR, CYP3A, and MDR1

SXR expression ^a	Tissues	Age/sex		CYP3A4		MDR1	
		Adult (years)	Fetus (weeks)	Adult	Fetus	Adult	Fetus
Positive	Liver	54/M	18/F	620.0	9.7	18.7	0.2
	Kidney	54/M	18/F	0.0	0.7	50.0	2.3
	Small intestine	24/M	18/F	112.7	10.0	20.3	2.0
	Large intestine	24/M	18/F	9.7	13.0	5.0	2.1
	Lung	54/M	14/M	0.8	1.0	1.9	0.3
	Trachea	54/M	b	0.0		0.4	
	Heart	54/M	18/F	0.0	0.0	0.1	1.5
	Aorta	24/M	b	0.0		0.3	
	Esophagus	24/M	b	0.4		1.8	
	Stomach	24/M	b	0.6		1.5	
	Brain	54/M	21/F	0.0	0.5	0.9	1.0
	Pancreas	54/M	18/F	0.1		2.5	
	Spleen	54/M	18/F	0.0	0.9	3.3	0.1
	Urinary bladder	54/M	b	0.0		0.7	
	Negative	Adrenal gland	54/M	21/M	0.7	0.4	1.7
Thyroid		54/M	18/M	0.0	1.9	1.2	0.9
Thymus		b	18/F		0.0		1.7
Testis		24/M	18/M	0.3	0.2	2.3	3.0
Prostate		24/M	b	0.6		3.4	
Mammary gland		38/F	b	0.0		10.1	
Fat		54/M	b	0.0		0.0	
Skin		54/M	b	0.0		0.0	
Muscle		15/F	b	0.0		0.7	
Umbilical cord			19/M		0.1		1.3

Data are expressed on the basis of GAPDH mRNA level (%).

^a SXR mRNA transcripts analyzed by real-time RT-PCR.

^b No specimens were available for study.

sciences Corp., NJ, USA) using Mini Trans-Blot Cell and Power/Pac 200 (Bio-Rad Laboratories Inc., CA, USA). Membranes were incubated with a 1:1000 dilution of human SXR antiserum (PXR, Santa Cruz Biotechnology, Inc., CA, USA) for overnight at 4 °C and a 1:1000 dilution of anti-goat IgG horseradish peroxidase (ICN Biomedicals, Inc., CA, USA) conjugated for one hour at room temperature. Protein bands were detected using the ECL Plus Western blotting detection reagent (Amersham Biosciences Corp.) and visualized with Las-1000 cooled CCD-camera chemiluminescent image analyzer (Fuji Photo Film Co., Ltd., Tokyo, Japan). The relative signal abundance was subsequently quantified as optical density (OD) value with Science Lab 99 Image Gauge 3.2 software (Fuji Photo Film Co., Ltd.). The intensity for SXR immunoreactivity was expressed as relative OD (arbitrary units).

2.4. Statistical analysis

Results were expressed as mean \pm S.D. Statistical analysis was performed with the StatView 5.0 J software (SAS Institute Inc., NC, USA). All data were analyzed by analysis of variance (ANOVA) followed by post-hoc Bonferroni/Dunn multiple comparison test. A p -value < 0.05 was considered to indicate statistical significance.

3. Results

3.1. Systemic distribution of SXR, CYP3A and MDR1 in human adult and fetal tissues

Results of semi-quantitative analysis of SXR, CYP3A and MDR1 in adult (male, 54 and 24 years old; female, 38 and 15 years old) and fetal (male, 18, 19, and 21 weeks old; female, 20 and 21 weeks old) human tissues are summarized in Table 3. Data are expressed relative to GAPDH mRNA levels in each specimen. Expression of SXR mRNA was detected in adult liver, kidney, and small/large intestine, but was below the limits of detection in other tissues examined. SXR mRNA transcripts in fetal tissues were limited to liver, kidney, and small/large intestine.

CYP3A4 mRNA was detected in adult lung, esophagus, stomach, small/large intestine, adrenal gland, testis, and prostate (28.3–112.7% of adult liver expression). In those fetal tissues where CYP3A4 expression was detected, the mRNA levels were comparable with those in adult tissues (lung, small/large intestine, liver, and adrenal gland 22.1–64.7%). Relatively low levels of CYP3A4 mRNA were detected in adult pancreas, fetal brain, spleen, kidney, thyroid, and testis (2.5–19.1%). CYP3A4 mRNA was also detected in placenta and umbilical cord (63.5 and 0.00%,




Fig. 1. Levels of mRNA for SXR, CYP3A4, and MDR1 in human fetal and adult tissues. (A) SXR mRNA levels in fetal tissues ($*p < 0.05$ vs. Li, K, Lu, and SI). (B) SXR mRNA levels in adult tissues ($*p < 0.05$ vs. K, Lu, and LI). (C) CYP3A4 mRNA levels in fetal tissues ($*p < 0.05$ vs. K and Lu). (D) CYP3A4 mRNA levels in adult tissues ($*p < 0.05$ vs. K, Lu, SI, and LI; a, 224 ± 61.9). (E) MDR1 mRNA levels in fetal tissues (there were no correlations among tissues examined). (F) MDR1 mRNA levels in adult tissues ($*p < 0.05$ vs. K, Lu, and LI). The number of each subjects was summarized as follows—Adult tissues: liver (Li), $n = 24$; kidney (K), $n = 24$; lung (Lu), $n = 24$; small intestine (SI), $n = 16$; large intestine (LI), $n = 16$. Fetal tissues: Li, $n = 8$; K, $n = 8$; Lu, $n = 8$; SI, $n = 5$; LI, $n = 5$. The data are expressed as the mean \pm S.D.

respectively). MDR1 mRNA expression was detected in nearly all the tissues examined with levels ranging from 11–82% of adult SXR liver levels (adult tissues) and 11–87% (fetal tissues).

3.2. Age and sex differences

The highest levels of SXR mRNA expression were detected in adult liver and small intestine, fetal small/large intestine with lower levels in the adult/fetal lung and fetal liver (Fig. 1A and B). The levels of CYP3A4 mRNA expression were also higher in adult liver and small intestine than other tissues examined (Fig. 1C and D). CYP3A4 mRNA levels were relatively low in fetal tissues including liver and small intestines (Fig. 1C). MDR1 mRNA expression was similar to that of CYP3A4 mRNA in the tissues where they were co-expressed with the highest levels in the adult liver and small intestine (Fig. 1E and F).

There were no significant differences detected between male and female subjects in any of the adult human tissues examined (data not shown).

3.2.1. SXR

SXR mRNA expression was low in fetal and neonatal livers. Its levels subsequently increased in the young to middle

age group and then decreased to fetal levels in the elderly group (Fig. 2A). In kidney, the levels of SXR mRNA expression were relatively high in the fetus, but decreased towards term (Fig. 2B). In lung, SXR mRNA levels remained relatively low but variable throughout life (Fig. 2C). High levels of SXR mRNA expression were detected in the small intestine of the young-middle group (Fig. 2D). In the large intestine, SXR mRNA was expressed at high levels in the fetal group and then decreased to lower levels after birth (Fig. 2E).

3.2.2. CYP3A4

In liver, CYP3A4 mRNA expression was also low in the fetus up to neonatal group. In the young group, the levels of CYP3A4 mRNA transcripts markedly varied but were in general higher than those in the middle group (Fig. 3A). In kidney, the levels of CYP3A4 mRNA expression were highly variable within and across age groups of the subjects examined (Fig. 3B). As with SXR, CYP3A4 of lung was expressed at relatively low levels (Fig. 3C). High levels of CYP3A4 mRNA were also detected in the young group small intestine (Fig. 3D). As with SXR, CYP3A4 mRNA was only expressed at high levels in the fetal large intestine (Fig. 3E).

3.2.3. MDR1

MDR1 mRNA expression was relatively high in the elderly group liver, but the differences were not statistically




Fig. 2. Changes in SXR mRNA levels in human adult and fetal tissues through development and aging. (A) In liver (* $p < 0.05$ vs. F, N, and EI groups); (B) in kidney (no development and aging affected SXR mRNA levels); (C) in lung (no development and aging affected SXR mRNA levels); (D) in small intestine (* $p < 0.05$ vs. N group); (E) in large intestine (* $p < 0.05$ vs. N, YM, and EI groups); (F) fetal; N, neonatal; Y, young; M, middle; EI, elderly; YM, young-middle. The numbers of each subject are summarized in Table 1b. The data are expressed as the mean \pm S.D.




Fig. 3. Changes in CYP3A4 mRNA levels of human adult and fetal tissues through development and aging. (A) In liver ($*p < 0.05$ vs. F and E groups; $†p < 0.05$ vs. N group); (B) in kidney ($*p < 0.05$ vs. F and E groups); (C) in lung (no development and aging affected CYP3A4 mRNA levels); (D) in small intestine (no development and aging affected CYP3A4 mRNA levels); (E) in large intestine ($*p < 0.05$ vs. N, YM, and EI groups); (F) fetal. N, neonatal; Y, young; M, middle; EI, elderly; YM, young-middle. The numbers of each subject are summarized in Table 1b. The data are expressed as the mean \pm S.D.

significant. In the neonatal group liver, MDR1 expression was relatively low but it increased with development and reached a plateau in the young group liver (Fig. 4A). The levels of MDR1 mRNA expression in kidney were low in fetus to neonatal group and later increased and remained relatively constant with maximal expression in the young group (Fig. 4B). In lung, MDR1 mRNA expression was very low in fetus but increased with development, and reached plateau in the young group and decreased thereafter (Fig. 4C). MDR1 expression levels were relatively low in both small and large intestine (Fig. 4D and E) throughout life with the exception of the small intestine in the young group.

3.3. Microdissection/PCR

Results of combined LCM/RT-PCR analysis of SXR, CYP3A4, and MDR1 in human kidney and small intestine are summarized in Table 4 and Fig. 5.

In adult human kidney, SXR PCR products were detected as a specific single band in whole kidney tissues and in urinary tubular epithelial cells isolated by LCM. SXR mRNA was reproducibly absent from the adult glomerulus whereas low levels of SXR mRNA expression were detected in stromal cells from one of three adult cases examined in our study (55

years old). CYP3A4 and MDR1 mRNAs were also detected in urinary tubular epithelial cells but not in the glomeruli. Low levels of CYP3A4 mRNA expression were also detected in stromal cells from one of three adults (55 years old), that also expressed SXR at low levels in these cells. SXR and CYP3A4 mRNAs were detected in urinary tubules and surrounding stromal cells in fetal kidney examined. MDR1 mRNA transcripts were detected only in the adult and fetal urinary tubules.

In adult small intestine, SXR and CYP3A4 mRNA expression were detected in surface epithelial cells, but not in tela submucosa and tunica muscularis. We could examine only one subject, but SXR and CYP3A4 mRNA expression were both detected in lamina propria mucosae of this 57-year-old male. MDR1 mRNA expression was restricted to surface epithelial cells. In the fetal small intestine, both SXR and CYP3A4 mRNA expression were detected in surface epithelial cells, but not in tunica muscularis. SXR and CYP3A4 mRNA were detected in the tela submucosa of fetal small intestine. MDR1 mRNA transcripts were restricted to surface epithelial cells as in the adult. Expression of GAPDH was detected in all the specimens examined in this combined LCM/RT-PCR analysis.




Fig. 4. Changes of MDR1 mRNA levels in human adult and fetal tissues through development and aging. There were no correlations between development and aging in MDR1 mRNA levels of liver (A), kidney (B), small intestine (D), and large intestine (E). In lung (C), a statistically significant difference was detected ($*p < 0.05$ vs. N, YM, and EI groups). F, fetal; N, neonatal; Y, young; M, middle; EI, elderly; YM, young-middle. The numbers of each subject are summarized in Table 1b. The data are expressed as the mean \pm S.D.

3.4. Immunoblotting analysis

Immunoblotting analysis demonstrated that expression of SXR protein (approximately 52 kDa) was detected in human liver, kidney, lung, small intestine, and large intestine, but was below the limits of detection in spleen and stomach (Fig. 6A). The highest levels of SXR immunoreactivity were detected in liver and small intestine with relatively lower levels in kidney. Weak immunoreactivity was detected in lung and large intestine. In spleen and stomach, SXR immunoreactivity was not detected [Fig. 6B (left)]. SXR protein expression was low in the fetal and 0-year-old liver, whereas high levels of SXR protein expression were detected in adult liver [Fig. 6C (left)]. Results of SXR immunoreactivity were consistent with those of SXR mRNA transcripts [Fig. 6B (right) and C (right)].

4. Discussion

SXR expression has been reported in human adult liver, small intestine, and large intestine by several groups of investigators (Bertilsson et al., 1998; Blumberg et al., 1998a; Lehmann et al., 1998). Our results were consistent with these results, but in this study we also detected SXR expression

in adult lung and kidney. In human liver, the levels of SXR, CYP3A4, and MDR1 mRNAs were all detected in both fetus and neonates. CYP3A7 was the major CYP3A form in fetal liver, and Hakkola et al. (2001) demonstrated that the abundance of CYP3A7 varied more markedly at the mRNA levels than at the protein level. CYP3A5 mRNA has been also reported in fetal liver, but the average level was 700-fold lower than that of CYP3A7 (Hakkola et al., 2001). In addition, CYP3A5 mRNA was detected only in a subset of the fetal liver specimens and its level was the lowest among CYP3A forms (Hakkola et al., 2001).

Bertilsson et al. (1998) demonstrated that in 10-week human embryos, expression was limited to the intestinal mucosal layer using in situ hybridization analysis. In our present LCM analysis, SXR mRNA was also detected in tela submucosa of fetal small intestine. In this study, we could also detect CYP3A4 and MDR1 mRNA transcripts in the adult and fetal intestinal epithelium. It is well known that the small intestine is one of the most important organs for the metabolism and clearance of both endogenous and exogenous substrates including steroids. This is consistent with the findings of our present study in that SXR, CYP3A4, and MDR1 mRNA transcripts were markedly present in adult and fetal small intestine. SXR and CYP3A4 mRNAs were also abundantly ex-

Table 4
Summary of laser capture microdissection/RT-PCR in human kidney and small intestine

	No.	Age	Sex	Kidney			Small intestine			
				G	T	S	E	PM	SM	M
SXR										
Adult	1	17	M	0	2	0				
	2	55	M	0	3	1				
	3	38	F	0	2	0				
	4	57	M				3	1	0	0
	5	76	M				3	^a	0	0
Fetus	6	21	M	0	1	2	3	^a	1	0
	7	21	F	0	1	2	3	^a	1	0
CYP3A4										
Adult	1	17	M	0	2	0				
	2	55	M	0	1	1				
	3	38	F	0	3	0				
	4	57	M				3	1	0	0
	5	76	M				3	^a	0	0
Fetus	6	21	M	0	1	1	2	^a	1	0
	7	21	F	0	1	1	2	^a	1	0
MDR1										
Adult	1	17	M	0	1	0				
	2	55	M	0	2	0				
	3	38	F	0	2	0				
	4	57	M				3	0	0	0
	5	76	M				3	^a	0	0
Fetus	6	21	M	0	1	0	1	^a	0	0
	7	21	F	0	1	0	1	^a	0	0

M, male; F, female; 0, negative; 1, weak; 2, moderate; 3, strong; G, glomerulus; T, urinary tubules; S, stromal cells; E, epithelium; PM, lamina propria; SM, tela submucosa; M, tunica muscularis. In kidney, adult, *n* = 3; fetus, *n* = 2. In small intestine, adult, *n* = 2; fetus, *n* = 2.

^a No specimens were available for study.

pressed in the fetal large intestine. The ability to absorb or digest nutrients is generally considered to be acquired from fetus to newborn in the small and large intestine (Babyatsky and Podolsky, 1999). In adult kidney, SXR mRNA transcripts were detected only in the urinary tubules whereas SXR transcripts were also detected in interstitial and stromal cells surrounding the urinary tubules in fetal kidney. CYP3A4 mRNA expression was considered dominant in adult urinary tubules, whereas it was dominant in the stromal cells of the fetal kidney. The possible roles of SXR and CYP3A4 in the fetal kidney may include an inactivation of steroids and xenobiotics, possibly leaking from the urinary tubules due to their immaturity.

It is known that the liver function, including xenobiotic metabolism decreases with aging. Moreover, neonatal liver is known to be immature in its ability to metabolize compounds (Greenblatt et al., 1982; Wynne et al., 1989; Sotaniemi et al., 1997; de Wildt et al., 1999). Our study suggests that SXR levels are at least partly responsible for these reductions in drug clearance in elderly subjects, but this also requires further investigations for confirmation. Individual differences




Fig. 5. (A) Toluidine blue staining for laser capture microdissection (LCM) in human kidney and small intestine. The numbers of each subject are summarized in Table 1b: (a) human adult kidney; (b) after microdissection; (c) after laser pressure cell transfer (GL, glomerulus; T, tubules; SC, stromal cells); (d) human fetal kidney; (e) human adult small intestine; (f) human fetal small intestine. (B) Results of electrophoresis of microdissection/RT-PCR. Results are summarized in Table 4. In adult kidney, mRNA expression for SXR, CYP3A4, and MDR were detected only in urinary tubules. In fetal kidney, mRNA expressions for SXR, CYP3A4, were detected in urinary tubules and stromal cells. MDR1 mRNA expression was detected only in urinary tubules. In adult small intestine, mRNA expression for SXR, CYP3A4, were detected in epithelium, and lamina propria mucosae (data not shown), and tunica muscularis in this case. MDR1 expression was detected only in surface epithelium. In fetal small intestine, mRNA expression for SXR, CYP3A4, were detected in epithelium, and tela submucosa. In all cases, GAPDH was detected as a specific single band. G, glomerulus; T, urinary tubules; S, stromal cells surrounding the urinary tubules; K, whole tissue of same kidney; E, epithelium; L, lamina propria mucosae of adult; S, tela submucosa of fetus; M, tunica muscularis; I, whole tissue of same small intestine; N.C., negative control; M, 100 bp ladder.

in the CYP enzymatic activities decrease with aging (Hunt et al., 1992). However, the differences of the amounts of CYPs detected in each age group examined were lower than expected in our study. Masuyama et al. (2003) reported that SXR was not detected in normal endometrium but was expressed in the endometrium of patients who took oral




Fig. 6. Results of immunoblotting analysis for SXR in human tissues. (A) Expression of protein for SXR was detected in adult (38-year-old women) liver, kidney, lung, small intestine, and large intestine (arrow head, 50 kDa). (B) The levels of SXR immunoreactivity were high in liver, kidney, and small intestine, low in lung and large intestine (left panel). SXR mRNA transcripts (right panel) were also detected in liver, kidney, lung, small intestine, and large intestine. (C) The levels of SXR protein and mRNA transcripts in adult and fetal livers. SXR protein expression was low in the fetal and 0-year-old livers, whereas the high levels of SXR protein expression were detected in adult livers (left panel). As with SXR protein expression patterns, SXR mRNA transcripts (right panel) were high in 15–44 years old, and low in fetus, 0, 63, and 86 years old. Small, small intestine; Large, large intestine; Marker, size marker. The numbers of each subject are summarized in Table 1b.

contraceptives. Masuyama et al. (2001) also reported the expression of PXR mRNA in reproductive organs such as the ovary, uterus, and placenta of non-pregnant and/or pregnant mice. These authors suggested that the steroid strongly influences SXR expression in human endometrium and rodent reproductive organs. Aging and/or maturation are associated with concomitant change in activities of steroid hormones in both male and female (Beitins et al., 1973; Hermann et al., 2000; Purohit and Reed, 2002). In addition, SXR transcripts have been reported from both normal breast tissue and breast carcinoma (Dotzlaw et al., 1999). Estradiol has traditionally been considered to play a critical role in female reproductive organs, normal breast, and breast cancer and is well known to activate SXR-dependent transcription (Blumberg et al., 1998a) and to be metabolized by CYP3A4 (Lee et al., 2001). These reported findings, taken together with the results presented above indicated that changes in SXR levels associated with the aging/maturation process may be related to physiological responses in the response to steroid and xenobiotic exposure.

Acknowledgments

We appreciated Mr. Katsuhiko Ono and Ms. Yoshiko Murakami, Department of Pathology, Tohoku University Graduate School of Medicine, for their skillful technical assistances. We also thank Dr. Andrew D. Darnel, BOZO (Biology and Zoology) Research Center, Inc. (Shizuoka, Japan), for technical advice regarding immunoblotting. This research was supported by Grant-in-aid for Health and Labor Sciences Research for Food and Chemical Safety (H13-Seikatsu-013) from Ministry of Health, Labor, and Welfare, Japan.

References

- Anttila, S., Hukkanen, J., Hakkola, J., Stjernvall, T., Beaune, P., Edwards, R.J., Boobis, A.R., Pelkonen, O., Raunio, H., 1997. Expression and localization of CYP3A4 and CYP3A5 in human lung. *Am. J. Respir. Cell Mol. Biol.* 16, 242–249.
- Babyatsky, M.W., Podolsky, D.K., 1999. Growth and development of the gastrointestinal tract. In: Yamada, T. (Ed.), *Textbook of Gastroen-*

- terology, 3rd ed. Liptoncott Williams and Wilkins, Philadelphia, pp. 547–584.
- Beitins, I.Z., Bayard, F., Ances, I.G., Kowarski, A., Migeon, C.J., 1973. The metabolic clearance rate, blood production, interconversion and transplacental passage of cortisol and cortisone in pregnancy near term. *Pediatr. Res.* 7, 509–519.
- Bertilsson, G., Heidrich, J., Svensson, K., Åsman, M., Jendeborg, L., Sydow-Bäckman, M., Ohlsson, R., Postlind, H., Blomquist, P., Berkenstam, A., 1998. Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. *Proc. Natl. Acad. Sci. U.S.A.* 95, 12208–12213.
- Blumberg, B., Sabbagh Jr., W., Juguilon, H., Bolado Jr., J., van Meter, C.M., Ong, E.S., Evans, R.M., 1998a. SXR, a novel steroid and xenobiotic-sensing nuclear receptor. *Gene Dev.* 12, 3195–3205.
- Blumberg, B., Kang, J., Bolado Jr., J., Chen, H., Craig, A.G., Moreno, T.A., Umesono, K., Parlmann, T., De Robertis, E.M., Evans, R.M., 1998b. BXR, an embryonic orphan nuclear receptor activated by novel class of endogenous benzoate metabolites. *Gene Dev.* 12, 1269–1277.
- Cordon-Cardo, C., O'Brien, J.P., Boccia, J., Casals, D., Bertino, J.R., Melamed, M.R., 1990. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. *J. Histochem. Cytochem.* 38, 1277–1287.
- de Wildt, S.N., Kearns, G.L., Leeder, J.S., van den Anker, J.N., 1999. Cytochrome P450 3A: ontogeny and drug disposition. *Clin. Pharmacokinet.* 37, 485–505.
- Domanski, T.L., Finta, C., Halpert, J.R., Zaphiropoulos, P.G., 2001. cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome P450. *Mol. Pharmacol.* 59, 386–392.
- Dotzlaw, H., Leygue, E., Watson, P., Murphy, L.C., 1999. The human orphan receptor PXR messenger RNA is expressed in both normal and neoplastic breast tissue. *Clin. Cancer Res.* 5, 2103–2107.
- Dussault, I., Forman, B.M., 2002. The nuclear receptor PXR: a master regulator of “homeland” defense. *Crit. Rev. Eukaryot. Gene Exp.* 12, 53–64.
- Emmert-Buck, M.R., Bonner, R.F., Smith, P.D., Chuaqui, R.F., Zhuang, Z., Goldstein, S.R., Weiss, R.A., Liotta, L.A., 1996. Laser capture microdissection. *Science* 274, 998–1001.
- Faneyte, I.F., Kristel, P., van de Vijver, M.J., 2001. Determining *MDR*/P-glycoprotein expression in breast cancer. *Int. J. Cancer* 93, 114–122.
- Geick, A., Eichelbaum, M., Burk, O., 2001. Nuclear receptor response elements mediate induction of intestinal *MDR1* by rifampin. *J. Biol. Chem.* 276, 14581–14587.
- Gellner, K., Eiselt, R., Hustert, E., Arnold, H., Koch, I., Haberl, M., Deglmann, C.J., Buck, O., Buntgefuss, D., Escher, S., Bishop, C., Koebe, H.G., Brinkmann, U., Klenk, H.P., Kleine, K., Meyer, U.A., Wojnowski, L., 2001. Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene. *Pharmacogenetics* 11, 111–121.
- Greenblatt, D.J., Sellers, E.M., Shader, R.I., 1982. Drug therapy: drug disposition in old age. *New Engl. J. Med.* 306, 1081–1088.
- Hakkola, J., Raunino, H., Purkunen, R., Saarikoski, S., Vahakangas, K., Pelkonen, O., Edwards, R.J., Boobis, A.R., Pasanen, M., 2001. Cytochrome P450 3A expression in the human fetal liver: evidence that CYP3A5 is expressed in only a limited number of fetal livers. *Biol. Neonate* 80, 193–201.
- Hermann, M., Untergasser, H., Rumpold, H., Berger, R.P., 2000. Aging of the male reproductive system. *Exp. Gerontol.* 35, 1267–1279.
- Hunt, C.M., Westerkam, W.R., Stave, G.M., Wilson, J.A., 1992. Hepatic cytochrome P-4503A (CYP3A) activity in the elderly. *Mech. Ageing Dev.* 64, 189–199.
- Kliewer, S.A., Goodwin, B., Willson, T.M., 2002. The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism. *Endocr. Rev.* 23, 687–702.
- Lee, A.J., Kosh, J.W., Conney, A.H., Zhu, B.T., 2001. Characterization of the NADPH-dependent metabolism of 17 β -estradiol to multiple metabolites by human liver microsomes and selectively expressed human cytochrome P450 3A4 and 3A5. *J. Pharmacol. Exp. Ther.* 298, 420–432.
- Lehmann, J.M., McKee, D.D., Watson, M.A., Willson, T.M., Moor, J.T., Kliewer, S.A., 1998. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interaction. *J. Clin. Invest.* 102, 1016–1023.
- Masuyama, H., Hiramatsu, Y., Mizutani, Y., Inoshita, H., Kudo, T., 2001. The expression of pregnane X receptor and its target gene, cytochrome P450 3A1, in perinatal mouse. *Mol. Cell Endocrinol.* 172, 47–56.
- Masuyama, H., Hiramatsu, Y., Kodama, J.-I., Kudo, T., 2003. Expression and potential roles of pregnane X receptor in endometrial cancer. *J. Clin. Endocrinol. Metab.* 88, 4446–4454.
- Michalets, E.L., 1998. Update: clinically significant cytochrome P-450 drug interaction. *Pharmacotherapy* 18, 84–112.
- Miki, Y., Nakata, T., Suzuki, T., Darnel, A.D., Moriya, T., Kaneko, C., Hidaka, K., Shiotsu, Y., Kusaka, H., Sasano, H., 2002. Systemic distribution of steroid sulfatase and estrogen sulfotransferase in human adult and fetal tissues. *J. Clin. Endocrinol. Metab.* 87, 5760–5768.
- Miyoshi, Y., Ando, A., Takamura, Y., Taguchi, T., Tamaki, Y., Noguchi, S., 2002. Prediction of response to docetaxel by CYP3A4 mRNA expression in breast cancer tissues. *Int. J. Cancer* 97, 129–132.
- Nelson, D.R., Koymans, L., Kamataki, T., Stegeman, J.J., Feyereisen, R., Waxman, D.J., Waterman, M.R., Gotoh, O., Coon, M.J., Estabrook, R.W., Gunsalus, I.C., Nebert, D.W., 1996. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. *Pharmacogenetics* 6, 1–42.
- Niino, Y., Irie, T., Takaishi, M., Hosono, T., Huh, N., Tachikawa, T., Kuroki, T., 2001. PKC θ II, a new isoform of protein kinase C specifically expressed in the seminiferous tubules of mouse testis. *J. Biol. Chem.* 276, 36711–36717.
- Osterheld, J.R., 1998. A review of developmental aspects of cytochrome P450. *J. Child Adolesc. Psychopharmacol.* 8, 161–174.
- Purohit, A., Reed, M.J., 2002. Regulation of estrogen synthesis in postmenopausal women. *Steroids* 67, 979–983.
- Sotaniemi, E.A., Arranto, A.J., Pelkonen, O., Pasanen, M., 1997. Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions. *Clin. Pharmacol. Ther.* 61, 331–339.
- Synold, T.W., Dussault, I., Forman, B.M., 2001. The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. *Nat. Med.* 7, 584–590.
- Thiebaut, F., Tsuruo, T., Hamada, H., Gottesman, M.M., Pastan, I., Willingham, M.C., 1987. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. *Proc. Natl. Acad. Sci. U.S.A.* 84, 7735–7738.
- van Kalken, C., Giaccone, G., van der Valk, P., Kuiper, C.M., Hadisaputro, M.M., Bosma, S.A., Scheper, R.J., Meijer, C.J., Pinedo, H.M., 1992. Multidrug resistance gene (P-glycoprotein) expression in the human fetus. *Am. J. Pathol.* 141, 1063–1072.
- Westlind, A., Malmbo, S., Johansson, I., Otter, C., Andersson, T.B., Ingelman-Sundberg, M., Oscarson, M., 2001. Cloning and tissue distribution of a novel human cytochrome p450 of the CYP3A subfamily, CYP3A43. *Biochem. Biophys. Res. Commun.* 281, 134–135.
- Willson, T.M., Kliewer, S.A., 2002. PXR, CAR and drug metabolism. *Nat. Rev. Drug Discov.* 1, 259–266.
- Wynne, H.A., Cope, L.H., Mutch, E., Rawlins, M.D., Woodhouse, K.W., James, O.F., 1989. The effect of age upon liver volume and apparent liver blood flow in healthy man. *Hepatology* 9, 297–301.
- Xie, W., Evans, R.M., 2001. Orphan nuclear receptors: the exotics of xenobiotics. *J. Biol. Chem.* 276, 37739–37742.